*The search scope is limited to the products and news section of this site
*The search scope is limited to the products and news section of this site
Recently, the 11th Chengdu New Drug Innovators Conference, as part of NDC2026, was successfully held. This conference brought together experts, scholars, and industry representatives in the biopharmaceutical field to jointly discuss cutting-edge R&D achievements and hot topics in the biopharmaceutical industry. Dr. Dang Qun, President of Genuine Biotech, was invited to attend the conference and deliver a presentation titled "Next-Generation Non-Camptothecin TOPO1 Inhibitors Designed for DXD-ADC Resistance by Using Artificial Intelligence Drug Discovery and Design (AIDD)", demonstrating the company's exploration of the novel TOPO1 inhibitor platform in overcoming the existing challenges of tumor resistance.
On Mar. 18, the "2026 Forbes China Pioneer Innovators in Industry Development Selection" was officially announced. Genuine Biotech, leveraging on its innovation performance, influence, and long-term development potential in the field of biomedicine, won the "2026 Forbes China Leading Enterprise in Industry Development" award.
Recently, the National Center for ADR Monitoring issued the "Announcement on Commending the Entities with Outstanding Performance in National Drug, Device, and Cosmetic Adverse Reaction Monitoring and Evaluation in 2025", and Genuine Biotech was rated as a "Drug, Device, and Cosmetic Enterprise with Outstanding Performance in Drug, Device, and Cosmetic Adverse Reaction Monitoring and Evaluation in 2025".
On Feb. 13, 2026, Henan Genuine Biotech Co., Ltd. announced that the clinical trial of self-developed anti-tumor drug GEN-725 tablets (Azvudine) in combination with PD-1 monoclonal antibody in the treatment of advanced solid tumors was approved by the National Medical Products Administration.
On January 21, 2026, Genuine Biotech officially announced that Mr. Gao Jun joined Genuine Biotech as Chief Financial Officer (CFO) to take charge of the Company's finance, capital operation, and compliance system improvement.
Annual Highlights of Genuine Biotech in 2025
During the conference, the "2025 Capital Market Most Valuable Influential List" was unveiled. Genuine Biotech won the "Most Investment Potential Award" for its outstanding performance and industry leadership.
Recently, the "Technology Empowers, Capital Breaks Through" sharing meeting sponsored by GuruClub was successfully held, during which the "Jinge Award" - the list of excellent companies of the year was officially unveiled, and Genuine Biotech won the "Excellent Biopharmaceutical Company of the Year" Award by virtue of its outstanding performance and professional strength in the biopharmaceutical field.
Recently, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted approval to Henan Genuine Biotech Co., Ltd. (Genuine Biotech) to initiate a Phase IIa clinical trial of its GEN-725 Tablets (Azvudine), intended for the treatment of hematological malignancies.
On 9 November, according to the disclosure from the Hong Kong Stock Exchange (HKEX), Genuine Biotech Limited (hereinafter referred to as "Genuine Biotech") has submitted its application for listing on the Main Board of HKEX, advancing an important step in the company's development.
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
